" class="no-js "lang="en-US"> Joe Mellor - Medtech Alert
Tuesday, September 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Shawn Levy

Joe Mellor

About Joe Mellor

Joseph Mellor works as a Co-founder & Chief Scientific Officer at seqWell, which is a Business Services company with an estimated 22 employees; and founded in 2014. They are part of the Research & Development team within the Engineering & Technical Department and their management level is C-Level. Joseph graduated from Boston University and is currently based in Beverly, United States.

Related Story

Industry News

 seqWell and Element Biosciences Partner to Demonstrate Sequencing Performance of Multiplexed plexWell Technology With the AVITI System | Pharmtech Focus

seqWell and Element Biosciences Partner to Demonstrate Sequencing Performance of Multiplexed plexWell Technology With the AVITI System

June 1 2022

seqWell, a global provider of genomic library workflow solutions including the plexWell™ next-generation sequencing (NGS) multiplexing technology, today […]